Monte Rosa Therapeutics (GLUE) director gets 25,800 options grant

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Monte Rosa Therapeutics director Anthony M. Manning received a grant of stock options for 25,800 shares of Common Stock. The options have an exercise price of $17.10 per share and expire on June 11, 2036. They vest in full on the earlier of June 11, 2027 or the company’s next annual meeting of stockholders, provided he continues in service until that time. Following this grant, he holds 25,800 derivative securities representing rights to acquire common shares.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Manning Anthony M.

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	25,800	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 25,800 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

Options granted: 25,800 options Exercise price: $17.10 per share Total derivative holdings: 25,800 options +2 more

5 metrics

Options granted 25,800 options Stock Option (Right to Buy) granted to director

Exercise price $17.10 per share Conversion or exercise price for common stock

Total derivative holdings 25,800 options Total shares following transaction

Expiration date June 11, 2036 Option expiration

Vesting date trigger June 11, 2027 Earlier of this date or next annual meeting

Key Terms

Stock Option (Right to Buy), exercise price, vesting, annual meeting of stockholders

4 terms

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)""

exercise price financial

"conversion_or_exercise_price: "17.1000""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"The shares subject to this option shall vest and become exercisable in full"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

annual meeting of stockholders regulatory

"the Issuer's next annual meeting of stockholders"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

06/12/2026 - 04:05 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Manning Anthony M.

(Last)

(First)

(Middle)

MONTE ROSA THERAPEUTICS, INC.

321 HARRISON AVENUE, SUITE 900

(Street)

BOSTON

MASSACHUSETTS

02118

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Monte Rosa Therapeutics, Inc. [ GLUE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$17.1	06/11/2026		A		25,800		⁽¹⁾	06/11/2036	Common Stock	25,800	$0	25,800	D

Explanation of Responses:

1. The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 11, 2027 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service at such time.

	/s/ Markus Warmuth, Attorney-in-Fact	06/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Monte Rosa Therapeutics (GLUE) disclose in this Form 4 filing?

Monte Rosa Therapeutics reported a director, Anthony M. Manning, received stock options for 25,800 shares. These options give him the right to buy common stock at a fixed $17.10 exercise price if and when they vest and are exercised.

How many Monte Rosa Therapeutics (GLUE) options were granted to the director?

Anthony M. Manning was granted options covering 25,800 shares of Monte Rosa common stock. The filing states his total derivative holdings after the transaction are 25,800 options, all tied to this new grant reported in the Form 4.

What is the exercise price of the new Monte Rosa (GLUE) stock options?

The stock options granted to director Anthony M. Manning have an exercise price of $17.10 per share. This is the fixed price he would pay to buy Monte Rosa common stock if he later exercises these options after they vest.

When do the newly granted Monte Rosa (GLUE) options vest?

The options vest in full on the earlier of June 11, 2027, or Monte Rosa’s next annual meeting of stockholders. Vesting is also conditioned on Anthony M. Manning’s continued service with the company through that vesting date, according to the filing footnote.

Do these Monte Rosa (GLUE) option grants involve an open-market stock purchase or sale?

No, the Form 4 describes a grant of stock options classified as an acquisition by award. The transaction code is “A,” indicating a compensation-related grant, not an open-market buy or sell of existing Monte Rosa common shares.

What is the expiration date of the Monte Rosa (GLUE) options granted to the director?

The options granted to Anthony M. Manning expire on June 11, 2036. After that date, any unexercised options will lapse and no longer give him the right to buy Monte Rosa common stock at the $17.10 exercise price.